- Home
- AGMB vs ADSE Comparison
AGMB vs ADSE Comparison
Compare AGMB & ADSE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AGMB | ADSE |
|---|---|---|
| Founded | 2017 | 1980 |
| Country | Belgium | Ireland |
| Employees | N/A | 302 |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Industrial Specialties |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 677.9M | 691.4M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | AGMB | ADSE |
|---|---|---|
| Price | $10.50 | $10.90 |
| Analyst Decision | Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $32.00 | N/A |
| AVG Volume (30 Days) | ★ 162.1K | 6.0K |
| Earning Date | 05-14-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $219.58 |
| Revenue Next Year | $33.33 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.00 | $7.89 |
| 52 Week High | $17.45 | $14.05 |
Technical Indicators
Market Signals| Indicator | AGMB | ADSE |
|---|---|---|
| Relative Strength Index (RSI) | 40.80 | 50.31 |
| Support Level | $9.71 | $11.07 |
| Resistance Level | $14.55 | $12.45 |
| Average True Range (ATR) | 1.42 | 0.64 |
| MACD | 0.03 | 0.06 |
| Stochastic Oscillator | 33.11 | 70.17 |
Price Performance
Historical ComparisonAbout AGMB AgomAb Therapeutics NV American Depositary Shares
AgomAb Therapeutics NV is a clinical-stage biopharmaceutical company focused on developing novel disease-modifying therapies for immunology and inflammatory diseases, with an initial focus on chronic fibrotic indications with high unmet medical need. Its product candidates are designed to target established pathways and utilize validated modalities, with a focus on addressing limitations associated with prior treatment approaches. The company's pipeline includes small molecule and antibody product candidates aimed at targets associated with fibrotic diseases. Key candidates include Ontunisertib (AGMB-129) and AGMB-447.
About ADSE ADS-TEC ENERGY PLC
ADS-TEC Energy PLC produces, develops, and markets battery-buffered EV charging systems infrastructure, battery storage systems, and cloud-based services that enable the customer to control and manage the system. ADSE generates revenue mainly through the sale of its products, services, and Big-LinX. Geographically, it derives a majority of its revenue from Germany.